How has been the historical performance of Eiko Lifescience?

Answer:The historical performance of Eiko Lifescience shows significant growth over the years, particularly from March 2018 to March 2025.

Breakdown:
Eiko Lifescience's net sales increased dramatically from 2.34 Cr in March 2018 to 37.66 Cr in March 2025, reflecting a strong upward trend. Total operating income followed a similar trajectory, rising from 2.34 Cr in March 2018 to 37.66 Cr in March 2025. The company's total expenditure also grew, from 1.99 Cr in March 2018 to 34.90 Cr in March 2025, but the operating profit (PBDIT) turned positive at 3.48 Cr in March 2025, compared to a loss of 4.50 Cr in March 2020. Profit before tax improved to 2.92 Cr in March 2025, up from a loss of 4.93 Cr in March 2020, leading to a profit after tax of 2.18 Cr in March 2025, a significant recovery from a loss of 3.62 Cr in March 2020. The earnings per share (EPS) also saw a turnaround, reaching 1.53 in March 2025 after being negative in the previous years. On the balance sheet, total assets increased from 10.95 Cr in March 2018 to 66.10 Cr in March 2025, while total liabilities rose from 10.95 Cr to 66.10 Cr in the same period. The cash flow from operating activities turned positive at 2.00 Cr in March 2025, despite a cash outflow from investing activities of 11.00 Cr. Overall, Eiko Lifescience demonstrated a strong recovery and growth trajectory in its financial performance over the analyzed years.